Reporter
-
Study describes how E. coli co-opts cells, causes recurrent UTIs
Researchers at Vanderbilt University Medical Center have discovered why the uropathogenic bacterium E. coli, the leading cause of urinary tract infections, is so tenacious; their findings could lead to new ways to prevent recurrent UTIs. Read MoreAug 25, 2022
-
Researchers discover how salt increases blood pressure
A Vanderbilt research team has discovered that activation of a certain protein complex involved in the inflammatory response in immune cells contributes to salt-sensitive hypertension. Read MoreAug 17, 2022
-
Video vital for telehealth visits
Vanderbilt study of 18,130 telehealth visits at the beginning of the COVID-19 pandemic defines risk factors associated with telehealth access and suggests how health systems can improve access. Read MoreJul 28, 2022
-
Specialty pharmacists help reduce MS relapse risk
Just one-third of patients with relapsing multiple sclerosis remain on disease-modifying therapy, and specialty pharmacists are in a unique position to help coordinate therapy discontinuation or change and reduce the risk of relapse. Read MoreJul 28, 2022
-
C. difficile may contribute to colorectal cancer: study
A Vanderbilt study found that the bacterium Clostridioides difficile (C. difficile) may be a previously unrecognized contributor to colorectal cancer. Read MoreJul 28, 2022
-
Study reveals need for matching targeted therapies with EGFR subtypes
A Vanderbilt study suggests that clinicians should take a deeper dive into distinguishing EGFR mutations when prescribing targeted therapies for non-small-cell lung cancers. Read MoreJul 28, 2022
-
Researchers find potential new target against colorectal cancer
Researchers at Vanderbilt University Medical Center have discovered a potential new target in the fight against colorectal cancer, the nation’s third most common malignancy and, next to lung cancer, the second leading cancer killer. Read MoreJul 21, 2022
-
Difficulty swallowing linked to chronic opioid use: study
Vanderbilt researchers found that chronic use of opioid painkillers like hydrocodone and oxycodone significantly increases the risk of dysphagia, or difficulty swallowing. Read MoreJul 21, 2022
-
Vanderbilt team tracks cellular and antibody responses to COVID-19 vaccine
A collaborative team of Vanderbilt researchers has characterized the antigen-specific immune response to the Pfizer SARS-CoV-2 RNA vaccine. The group used multiple single-cell technologies, unbiased machine learning and traditional immunological approaches to track cellular and antibody responses in samples collected over time from a cohort of healthy participants. Read MoreJul 20, 2022
-
Study reveals how gastric cancer forms, suggests preventive treatment
Eunyoung Choi, PhD, assistant professor of Surgery, and colleagues identified for the first time that Trop2+/CD133+/CD166+ dysplastic stem cells are a key source of clonal evolution of dysplasia to multiple types of gastric cancer. Read MoreJun 23, 2022
-
Five-year, multi-site trial to assess lymphedema prevention concludes
Lymphedema study results could be a game-changer for breast cancer patients and survivors. The Vanderbilt-led trial found that patients with early detection who used L-Dex with additional intervention were less likely to progress to chronic lymphedema than patients monitored with a tape measure receiving the same intervention. Read MoreJun 20, 2022
-
Study finds administering IV fluids during emergency tracheal intubation does not lower cardiac arrest risk
Rapidly administering IV fluids to critically ill adults undergoing emergency tracheal intubation does not significantly decrease chances of hypotension (low blood pressure) and cardiac arrest, a Vanderbilt University Medical Center-led study shows. Read MoreJun 20, 2022
-
Study measures Alzheimer’s risk reductions associated with healthy lifestyles
Reported June 13 in Neurology, an Alzheimer’s disease risk study from Vanderbilt University Medical Center measures significantly reduced risk associated with healthy lifestyles, including non-smoking, leisure-time exercise, low-to-moderate alcohol consumption, adequate sleep and healthy diet. Read MoreJun 13, 2022
-
Filling multiple opioid prescriptions after childbirth associated with maternal death risk
In a new study led by Vanderbilt University Medical Center researchers, women who filled two or more prescriptions for opioids after childbirth faced a 46% greater risk of death than women who did not. Read MoreJun 9, 2022
-
Genes and age studied as markers for higher death rate in those with atrial fibrillation
Younger patients with atrial fibrillation who had rare genetic variants associated with inherited cardiomyopathy and arrythmia syndromes were associated with a significantly higher rate of death than those without the variants, a Vanderbilt-led study has shown. Read MoreJun 8, 2022
-
Research probes cause of acute flaccid myelitis in children
Research that began at Vanderbilt University Medical Center has found evidence that a viral infection followed by a “robust” immune response is the cause of a polio-like paralyzing illness in children called acute flaccid myelitis (AFM). Read MoreJun 8, 2022
-
Molecular ‘switch’ may illuminate stomach disorders
An international team that included researchers from Vanderbilt University Medical Center has discovered a molecular switch that induces rapid proliferation of zymogen granule-secreting chief cells in the stomach to regenerate damaged tissue. Read MoreMay 19, 2022
-
Study identifies first cellular “chaperone” for zinc, sheds light on worldwide public health problem of zinc deficiency
A team led by Vanderbilt researchers has described and characterized the first zinc metallochaperone: a protein that puts zinc into other “client” proteins. Read MoreMay 17, 2022
-
Study sheds light on the dark side of obesity
Vanderbilt research that promotes the anti-inflammatory pathway in macrophages could also reduce some of the bad side effects of obesity. Read MoreMay 12, 2022
-
VUMC-led study finds Moderna COVID vaccine safe and effective for children
Moderna’s COVID-19 vaccine is safe and generates robust immune responses in children ages 6 to 11 years, a national clinical trial co-led by C. Buddy Creech, MD, MPH, has found. Read MoreMay 12, 2022